Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Middle East Health Journal.
Press releases published on April 24, 2025
Autonomix Medical, Inc. Technology and Early Proof-of-Concept Study Results to be Featured in Poster Presentation at the World-Leading Course in Interventional Cardiovascular Medicine, EuroPCR
GlobeNewswire
·
April 24, 2025
THE WOODLANDS, TX, April 24, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced its technology and early proof- …
SS Innovations to Uplist to Nasdaq
GlobeNewswire
·
April 24, 2025
FORT LAUDERDALE, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (OTC: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and …
Sofwave’s liftHD Body Contouring Applicator to Debut at the 44th Annual Meeting of the American Society for Laser Medicine and Surgery (ASLMS) 2025
GlobeNewswire
·
April 24, 2025
Launch of the liftHD body applicator provides opportunity for next generation non-invasive aesthetic body treatments which improve cellulite and skin laxity appearance in order to achieve SUPERB results beyond the face Four abstract poster presentations …
Paralyzed Israeli Soldier Walks Again with Use of the ReWalk Personal Exoskeleton
GlobeNewswire
·
April 24, 2025
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, April 24, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or …
VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market
GlobeNewswire
·
April 24, 2025
SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company”) announced that it has emerged from stealth mode to dramatically impact drug discovery and development. VivoSim will offer liver and intestinal toxicology …
Axogen, Inc. to report 2025 first quarter financial results on May 8, 2025
GlobeNewswire
·
April 24, 2025
ALACHUA and TAMPA, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report 2025 first quarter …
X4 Pharmaceuticals to Report First-Quarter 2025 Financial Results and Host Conference Call and Webcast on May 1, 2025
GlobeNewswire
·
April 24, 2025
BOSTON, April 24, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will report financial results for the first quarter ended March …
Ardelyx Announces Three Abstracts Accepted for Poster Presentations at Digestive Disease Week 2025 Conference
GlobeNewswire
·
April 24, 2025
WALTHAM, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today …
Northstrive Biosciences Announces Positive FDA Response Supporting A Submission of IND for a Phase 2 Clinical Trial for EL-22 in Combination with GLP-1 Receptor Agonist for Obesity Treatment
GlobeNewswire
·
April 24, 2025
Northstrive Biosciences received preliminary meeting responses from the FDA regarding Northstrive’s nonclinical studies and clinical development plans for EL-22, administered in combination with GLP-1 receptor agonists. Northstrive believes the FDA …
SpyGlass Pharma Presents 18-Month Data Demonstrating Compelling Visual Acuity Results with Their IOL-mounted Innovative Drug Delivery Platform
GlobeNewswire
·
April 24, 2025
All patients achieved 20/30 or better best corrected distance visual acuity (BCDVA) Significant IOP reduction at 18 months was also demonstrated with 100% of patients off all topical IOP-lowering medication ALISO VIEJO, Calif., April 24, 2025 (GLOBE …
NephroDI Therapeutics’ Founder and CMO Jeff M. Sands, M.D. Receives the 2025 Robert W. Berliner Award for Excellence in Renal Physiology
GlobeNewswire
·
April 24, 2025
April 25, 2025, Seattle, WA – NephroDI Therapeutics (NephroDI), a pharmaceutical company focusing on kidney disorders, announces that its Founder and CMO, Jeff M. Sands, M.D., is the recipient of the 2025 Robert W. Berliner Award for Excellence in Renal …
Esperion Unveils Promising Research Supporting Lead Development Candidates for Primary Sclerosing Cholangitis (PSC) at R&D Day 2025
GlobeNewswire
·
April 24, 2025
– Expands Development Portfolio with Introduction of a Novel Program Targeting PSC – – Confirms Highly Specific Allosteric ACLY Inhibitor Shown to Reduce Liver Injury, Inflammation and Fibrosis Across Multiple PSC-Relevant Pre-Clinical Models – – …
BioAtla Announces Poster Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting
GlobeNewswire
·
April 24, 2025
SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today …
Cidara Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 8, 2025
GlobeNewswire
·
April 24, 2025
SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced that it will report its first …
Cocrystal Pharma’s Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants
GlobeNewswire
·
April 24, 2025
Norovirus GII.17 variants have overtaken GII.4 as the most prevalent strain and significantly increased norovirus outbreaks in the U.S. and European countries in 2024-2025 Cocrystal Pharma’s pan-viral protease inhibitor CDI-988 shows superior broad- …
Carterra Announces its 2025 Symposia Series on Speeding Drug Discovery with AI/ML and Other New Technologies
GlobeNewswire
·
April 24, 2025
Presentations will be delivered by experts from a wide variety of leading research groups including Pfizer, GSK, and Bio-Techne, along with co-hosts IPA, ACROBiosystems, and Curia. SALT LAKE CITY, April 24, 2025 (GLOBE NEWSWIRE) -- Carterra Inc., the world …
CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Monday, April 28, 2025
GlobeNewswire
·
April 24, 2025
IRVINE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer …
Collegium to Report First Quarter 2025 Financial Results on May 8, 2025
GlobeNewswire
·
April 24, 2025
STOUGHTON, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report first quarter 2025 financial results after the market closes on Thursday, May 8, 2025. Following the release of the …
Cronos Group Inc. to Hold 2025 First Quarter Earnings Conference Call on May 8, 2025
GlobeNewswire
·
April 24, 2025
TORONTO, April 24, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) will hold its 2025 first quarter earnings conference call on Thursday, May 8, 2025 at 8:30 a.m. ET. Cronos’ senior management team will …
Krystal Biotech to Present at Upcoming Scientific Conferences
GlobeNewswire
·
April 24, 2025
PITTSBURGH, April 24, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the Company will be presenting on multiple programs in the lung, eye, and skin at upcoming scientific conferences being held in May and …